Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?

Ma and colleagues reported in their study on 12,004 elderly patients published on Breast J. 2020, that adjuvant chemotherapy was not associated with overall survival. Given the toxicities associated with systemic treatments, caution recommendation or omission of chemotherapy may be considered in eld...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roberta Maltoni, Sara Ravaioli, Giuseppe Bronte, Massimiliano Mazza, Claudio Cerchione, Ilaria Massa, William Balzi, Michela Cortesi, Michele Zanoni, Sara Bravaccini
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Chronological age Biological age Breast cancer Elderly patients Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/48243069127b4c598fed7ca309fde0fd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:48243069127b4c598fed7ca309fde0fd
record_format	dspace
spelling	oai:doaj.org-article:48243069127b4c598fed7ca309fde0fd2021-12-02T05:00:23ZChronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?1936-523310.1016/j.tranon.2021.101300https://doaj.org/article/48243069127b4c598fed7ca309fde0fd2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1936523321002916https://doaj.org/toc/1936-5233Ma and colleagues reported in their study on 12,004 elderly patients published on Breast J. 2020, that adjuvant chemotherapy was not associated with overall survival. Given the toxicities associated with systemic treatments, caution recommendation or omission of chemotherapy may be considered in elderly patient selection especially when comorbidities are present. We agree with authors final conclusions but we want to highlight that to define the adjuvant therapy in BC elderly patients several factors need to be taken into account. One of the main issues is the lack of universal and unique guidelines to define elderly patients. In clinical practice it can be very difficult to estimate the benefit/risk ratio in elderly patients because chemotherapy-induced toxicity is worse than in younger individuals. For these reasons, beyond comorbidities, the choice of adjuvant therapy for elderly patients must also be based both on chronological and biological age. Moreover, the multidisciplinary team for the elderly patient evaluation should include both the geriatrician and the molecular biologist.Roberta MaltoniSara RavaioliGiuseppe BronteMassimiliano MazzaClaudio CerchioneIlaria MassaWilliam BalziMichela CortesiMichele ZanoniSara BravacciniElsevierarticleChronological ageBiological ageBreast cancerElderly patientsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101300- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chronological age Biological age Breast cancer Elderly patients Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Chronological age Biological age Breast cancer Elderly patients Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Roberta Maltoni Sara Ravaioli Giuseppe Bronte Massimiliano Mazza Claudio Cerchione Ilaria Massa William Balzi Michela Cortesi Michele Zanoni Sara Bravaccini Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
description	Ma and colleagues reported in their study on 12,004 elderly patients published on Breast J. 2020, that adjuvant chemotherapy was not associated with overall survival. Given the toxicities associated with systemic treatments, caution recommendation or omission of chemotherapy may be considered in elderly patient selection especially when comorbidities are present. We agree with authors final conclusions but we want to highlight that to define the adjuvant therapy in BC elderly patients several factors need to be taken into account. One of the main issues is the lack of universal and unique guidelines to define elderly patients. In clinical practice it can be very difficult to estimate the benefit/risk ratio in elderly patients because chemotherapy-induced toxicity is worse than in younger individuals. For these reasons, beyond comorbidities, the choice of adjuvant therapy for elderly patients must also be based both on chronological and biological age. Moreover, the multidisciplinary team for the elderly patient evaluation should include both the geriatrician and the molecular biologist.
format	article
author	Roberta Maltoni Sara Ravaioli Giuseppe Bronte Massimiliano Mazza Claudio Cerchione Ilaria Massa William Balzi Michela Cortesi Michele Zanoni Sara Bravaccini
author_facet	Roberta Maltoni Sara Ravaioli Giuseppe Bronte Massimiliano Mazza Claudio Cerchione Ilaria Massa William Balzi Michela Cortesi Michele Zanoni Sara Bravaccini
author_sort	Roberta Maltoni
title	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
title_short	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
title_full	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
title_fullStr	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
title_full_unstemmed	Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
title_sort	chronological age or biological age: what drives the choice of adjuvant treatment in elderly breast cancer patients?
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/48243069127b4c598fed7ca309fde0fd
work_keys_str_mv	AT robertamaltoni chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT sararavaioli chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT giuseppebronte chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT massimilianomazza chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT claudiocerchione chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT ilariamassa chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT williambalzi chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT michelacortesi chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT michelezanoni chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients AT sarabravaccini chronologicalageorbiologicalagewhatdrivesthechoiceofadjuvanttreatmentinelderlybreastcancerpatients
_version_	1718400825997393920

Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?

Ejemplares similares